Serum effects confound the neuroleptic radioreceptor assay

Richard Mailman, Diane L. DeHaven, Emily A. Halperin, Mark H. Lewis

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The neuroleptic radioreceptor assay (NRRA) is used widely to monitor total neuroleptic-like activity (NLA) in patients taking one or more antipsychotic drugs. The original report of Creese and Snyder (1) stated that serum alone caused a small effect on binding which was negligible compared to normal daily variations in the assay. Conversely, in studies with striata from rat or cow brain, we found that sera from healthy, drug free volunteers, when used at 50 μL/ 1 mL assay volume, caused marked inhibition of binding. although any sample of serum causes reproducible inhibition with a given preparation of bovine or rat striatal membranes, the effects of various serum samples may differ markedly when several striatal membrane preparations are compared. Moreover, samples taken from people at different times may also vary, although less than the interindividual differences. Despite this variance, the slopes of log-logit plots were equal to 1 either in the presence or absence of serum. Because of the differences in the interaction of individual sera with different membrane preparations, it is difficult to compensate accurately for this serum effect by simply including control serum in the standard curve. Thus, the use of the NRRA as a quantitative tool in the clinical pharmacology of neuroleptics may be limited by this non-specific effect of serum, and this finding may offer one explanation for some of the inconsistencies found in comparing the NRRA with direct analytical methods.

Original languageEnglish (US)
Pages (from-to)1057-1064
Number of pages8
JournalLife Sciences
Volume34
Issue number11
DOIs
StatePublished - Mar 12 1984

Fingerprint

Radioligand Assay
Antipsychotic Agents
Assays
Serum
Membranes
Corpus Striatum
Rats
Brain
Clinical Pharmacology
Volunteers
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

Mailman, Richard ; DeHaven, Diane L. ; Halperin, Emily A. ; Lewis, Mark H. / Serum effects confound the neuroleptic radioreceptor assay. In: Life Sciences. 1984 ; Vol. 34, No. 11. pp. 1057-1064.
@article{bec9bf9767b64f348015fb3e316108dd,
title = "Serum effects confound the neuroleptic radioreceptor assay",
abstract = "The neuroleptic radioreceptor assay (NRRA) is used widely to monitor total neuroleptic-like activity (NLA) in patients taking one or more antipsychotic drugs. The original report of Creese and Snyder (1) stated that serum alone caused a small effect on binding which was negligible compared to normal daily variations in the assay. Conversely, in studies with striata from rat or cow brain, we found that sera from healthy, drug free volunteers, when used at 50 μL/ 1 mL assay volume, caused marked inhibition of binding. although any sample of serum causes reproducible inhibition with a given preparation of bovine or rat striatal membranes, the effects of various serum samples may differ markedly when several striatal membrane preparations are compared. Moreover, samples taken from people at different times may also vary, although less than the interindividual differences. Despite this variance, the slopes of log-logit plots were equal to 1 either in the presence or absence of serum. Because of the differences in the interaction of individual sera with different membrane preparations, it is difficult to compensate accurately for this serum effect by simply including control serum in the standard curve. Thus, the use of the NRRA as a quantitative tool in the clinical pharmacology of neuroleptics may be limited by this non-specific effect of serum, and this finding may offer one explanation for some of the inconsistencies found in comparing the NRRA with direct analytical methods.",
author = "Richard Mailman and DeHaven, {Diane L.} and Halperin, {Emily A.} and Lewis, {Mark H.}",
year = "1984",
month = "3",
day = "12",
doi = "10.1016/0024-3205(84)90019-5",
language = "English (US)",
volume = "34",
pages = "1057--1064",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "11",

}

Mailman, R, DeHaven, DL, Halperin, EA & Lewis, MH 1984, 'Serum effects confound the neuroleptic radioreceptor assay', Life Sciences, vol. 34, no. 11, pp. 1057-1064. https://doi.org/10.1016/0024-3205(84)90019-5

Serum effects confound the neuroleptic radioreceptor assay. / Mailman, Richard; DeHaven, Diane L.; Halperin, Emily A.; Lewis, Mark H.

In: Life Sciences, Vol. 34, No. 11, 12.03.1984, p. 1057-1064.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Serum effects confound the neuroleptic radioreceptor assay

AU - Mailman, Richard

AU - DeHaven, Diane L.

AU - Halperin, Emily A.

AU - Lewis, Mark H.

PY - 1984/3/12

Y1 - 1984/3/12

N2 - The neuroleptic radioreceptor assay (NRRA) is used widely to monitor total neuroleptic-like activity (NLA) in patients taking one or more antipsychotic drugs. The original report of Creese and Snyder (1) stated that serum alone caused a small effect on binding which was negligible compared to normal daily variations in the assay. Conversely, in studies with striata from rat or cow brain, we found that sera from healthy, drug free volunteers, when used at 50 μL/ 1 mL assay volume, caused marked inhibition of binding. although any sample of serum causes reproducible inhibition with a given preparation of bovine or rat striatal membranes, the effects of various serum samples may differ markedly when several striatal membrane preparations are compared. Moreover, samples taken from people at different times may also vary, although less than the interindividual differences. Despite this variance, the slopes of log-logit plots were equal to 1 either in the presence or absence of serum. Because of the differences in the interaction of individual sera with different membrane preparations, it is difficult to compensate accurately for this serum effect by simply including control serum in the standard curve. Thus, the use of the NRRA as a quantitative tool in the clinical pharmacology of neuroleptics may be limited by this non-specific effect of serum, and this finding may offer one explanation for some of the inconsistencies found in comparing the NRRA with direct analytical methods.

AB - The neuroleptic radioreceptor assay (NRRA) is used widely to monitor total neuroleptic-like activity (NLA) in patients taking one or more antipsychotic drugs. The original report of Creese and Snyder (1) stated that serum alone caused a small effect on binding which was negligible compared to normal daily variations in the assay. Conversely, in studies with striata from rat or cow brain, we found that sera from healthy, drug free volunteers, when used at 50 μL/ 1 mL assay volume, caused marked inhibition of binding. although any sample of serum causes reproducible inhibition with a given preparation of bovine or rat striatal membranes, the effects of various serum samples may differ markedly when several striatal membrane preparations are compared. Moreover, samples taken from people at different times may also vary, although less than the interindividual differences. Despite this variance, the slopes of log-logit plots were equal to 1 either in the presence or absence of serum. Because of the differences in the interaction of individual sera with different membrane preparations, it is difficult to compensate accurately for this serum effect by simply including control serum in the standard curve. Thus, the use of the NRRA as a quantitative tool in the clinical pharmacology of neuroleptics may be limited by this non-specific effect of serum, and this finding may offer one explanation for some of the inconsistencies found in comparing the NRRA with direct analytical methods.

UR - http://www.scopus.com/inward/record.url?scp=0021363513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021363513&partnerID=8YFLogxK

U2 - 10.1016/0024-3205(84)90019-5

DO - 10.1016/0024-3205(84)90019-5

M3 - Article

C2 - 6142394

AN - SCOPUS:0021363513

VL - 34

SP - 1057

EP - 1064

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 11

ER -